Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously ...

In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential ...

In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple ...

Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of ...